Transcranial Magnetic Stimulation (TMS)

Policy MP-001

Origination Date: 4/9/18

Current Effective Date: 8/1/19

Next Review Date: 8/1/20

Disclaimer:
1. Policies are subject to change without notice.
2. Policies outline coverage determinations for U of U Health Plans Commercial, and Healthy U (Medicaid) plans. Refer to the “Policy” section for more information.

Description:
Transcranial magnetic stimulation (TMS) is a non-invasive method of induction of a focal current in the brain and transient modulation of the function of the targeted cerebral cortex. This procedure entails placement of an electromagnetic coil on the scalp; high-intensity electrical current is rapidly turned on and off in the coil through the discharge of capacitors. Depending on stimulation parameters (frequency, intensity, pulse duration, stimulation site), repetitive TMS (rTMS) to specific cortical regions can either increase or decrease the excitability of the affected brain structures.

Transcranial magnetic stimulation has been investigated in the treatment of various psychiatric disorders, especially depression. This procedure is usually carried out in an outpatient setting. In contrast to electroconvulsive therapy, TMS does not require anesthesia or analgesia. Furthermore, it does not affect memory and usually does not cause seizures. However, the available peer-reviewed medical literature has not established the effectiveness of rTMS in the treatment of psychiatric disorders other than major depression. In addition, more research is needed to ascertain the roles of various stimulation parameters of rTMS for its optimal outcome as well as its long-term effectiveness in the treatment of psychiatric disorders.

Policy Statement and Criteria

1. Commercial Plans

   U of U Health Plans covers repetitive transcranial magnetic stimulation when the following criteria for Initial Coverage is met (must meet ALL):

   A. Patient is 18 years of age or older;

   B. Treatment is provided by a licensed psychiatrist or Psychiatric Advanced Practice Registered Nurse (APRN);

   C. TMS device is FDA approved;
D. Request is for unilateral repetitive Transcranial Magnetic Stimulation (rTMS);
E. Diagnosis of major depressive disorder without psychosis (that meets the DSM-5 definition*) by a licensed mental health professional, (Psychiatrist or APRN);
F. Failure of Medication Therapy defined by one of the following:
   1) Documented failure of at least 4 psychopharmacologic agent trials of adequate dose and duration (>4 weeks) from two different agent classes in the current episode;
   2) Written documentation of an inability to tolerate psychopharmacologic agents as evidenced by four or more lifetime trials with distinctive side effects.
G. Member has no contraindications to rTMS such as:
   1) Seizure disorder/epilepsy;
   2) Pregnant or nursing;
   3) No vagus nerve stimulator leads in carotid sheath;
   4) No Conductive, ferromagnetic or other magnetic-sensitive metals implanted or embedded in the head within 30 cm of the TMS coil placement other than dental fillings (examples include metal plates, cochlear or ocular implants, deep brain stimulators, vagus nerve stimulator, staples, stents, etc.);
   5) Neurological conditions (e.g., dementia, primary/secondary tumor in the central nervous system, cerebrovascular disease, history of repetitive/severe head trauma, or increased intracranial pressure);
   6) High alcohol or illicit drug consumption;
   7) Suicidal ideations; or
   8) Acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in current depressive episode.

**Maximum number of therapy sessions to be approved is 36 within an 8 week time period.**

Criteria for repeat coverage:
A. Patient has previously undergone full course of rTMS and had a positive response defined by the use of appropriate standardized scales with testing dates of service;
B. Request > 6 months since previous treatment.
U of U Health Plans does not cover unilateral repetitive transcranial magnetic stimulation for any other behavioral health indication as it is considered investigational.

U of U Health Plans does not cover bilateral repetitive transcranial magnetic stimulation for any behavioral health condition as it is unproven and considered investigational.

U of U Health Plans does not cover navigated transcranial magnetic stimulation as it is considered experimental/investigational for motor function mapping and/or treatment planning of neurological diseases/disorders because it’s value and effectiveness has not been established.

*DSM V definition of major depressive disorder (Please click on the following pdf):

DSM5_DiagnosticCriteria_MajorDepress

2. Medicaid Plans
As major depressive disorder is a carved out behavioral health condition, this treatment is not covered by U of U Health Plans /HealthyU Medicaid.

Clinical Rationale
From the point of a systematic review perspective, In a Directory Report (Hayes 2016) on left repetitive high-frequency left transcranial magnetic stimulation (HFL-rTMS) for treatment-resistant depression, Hayes concluded that HFL-rTMS has a modest positive benefit, reducing the symptoms of depression, as a monotherapy and as an add-on therapy. According to Hayes, the quality of the large body of evidence was moderate, including 15 randomized, sham controlled trials (n=30–301). The evidence was insufficient to support HFL-rTMS for maintenance therapy to prevent relapse.

Another directory report on comparative effectiveness of HFL-rTMS (Hayes, 2016) reported that there was insufficient evidence to support the use of HFL-rTMS combined with ECT compared to ECT alone for treatment-resistant major depressive disorder. The conclusion was based on ten randomized controlled trials with small patient populations (n=32–121). Various outcome criteria and treatment regimens for rTMS and ECT were used.

Seven randomized controlled trials (n=26-170) were included from a technology brief (Hayes, 2016) on low frequency rTMS (LFrTMS) (1 Hz). The studies reported that LFrTMS, in addition to pharmacotherapy, produced antidepressant effects. However, results were mixed suggesting no difference between LFrTMS and sham therapy as an adjuvant therapy to antidepressant treatment. Results also suggested that there was no difference between LFrTMS and HFrTMS as an add-on therapy. The low-quality evidence did not allow definitive conclusions regarding the efficacy of LFrTMS as a monotherapy. The therapies appeared safe with mild adverse events (e.g., scalp discomfort, transitory headaches).
In a search and summary report on navigated Transcranial Magnetic Stimulation (nTMS) (Hayes, 2016), reported that although there was a moderate amount of published evidence, well-designed, large randomized controlled trials are lacking. A review of the abstracts showed conflicting findings. There was considerable overlap of authorship in the retrieved abstracts, and the majority of the published studies consisted of small patient populations with various diagnosis.

The American Psychiatric Association practice guideline on major depression (2010, reaffirmed 2015) stated: "For patients whose symptoms have not responded adequately to medication, ECT remains the most effective form of therapy and should be considered. In patients capable of adhering to dietary and medication restrictions, an additional option is changing to a nonselective MAOI after allowing sufficient time between medications to avoid deleterious interactions. Transdermal selegiline, a relatively selective MAO B inhibitor with fewer dietary and medication restrictions, or transcranial magnetic stimulation could also be considered. Based on the results of a multisite randomized sham-controlled clinical trial of high-frequency TMS over the left dorsolateral prefrontal cortex, TMS was cleared by the FDA in 2008 for use in individuals with major depressive disorder who have not had a satisfactory response to at least one antidepressant trial in the current episode of illness. However, another large randomized sham-controlled trial of TMS added to antidepressant pharmacotherapy showed no significant benefit of left dorsolateral prefrontal cortex TMS. In comparisons of actual TMS versus sham TMS, most but not all recent meta-analyses have found relatively small to moderate benefits of TMS in terms of clinical response. Although the primary studies used in these meta-analyses are highly overlapping and the variability in TMS stimulus parameters and treat treatment paradigms complicates the interpretation of research findings, these meta-analyses also support the use of high-frequency TMS over the left dorsolateral prefrontal cortex. Lesser degrees of treatment resistance may be associated with a better acute response to TMS. In comparison with ECT, TMS has been found in randomized studies to be either less effective than ECT or comparable in efficacy to ECT, but in the latter studies TMS was more effective and ECT was less effective than is typically seen in clinical trials. A few number of studies have compared cognitive effects of TMS and ECT. One randomized trial found no significant difference between TMS and non-dominant unilateral ECT on performance on neuropsychological tests at 2 and at 4 weeks of treatment, although a small open-label trial reported a greater degree of memory difficulties with ECT than with TMS shortly after the treatment course."

In addition, the National Institute for Health and Care Excellence (NICE) issued an interventional procedural guidance document on TMS for treating and preventing migraines (January 2014). The authors reported that the evidence on the efficacy of TMS for the treatment of migraine and prevention of migraine is limited. Evidence on its safety in the short and medium term is adequate but there is uncertainty about the safety of long-term or frequent use of TMS. Nice concluded that the procedure should only be used with special arrangements for clinical governance, consent and audit or research.

NICE also concluded in 2015 that the evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns, and that the evidence on its efficacy in the short-term is adequate, although the clinical response is variable (NICE, 2015). The assessment found little data on the efficacy in the long-term and during the consent process, clinicians should, in particular, inform patients about the other treatment options available, and make sure that patients understand the possibility the procedure may not give them benefit. The assessment also cited the need for publication of further evidence on patient selection, details of the precise type and regime of stimulation used, the use of maintenance treatment and long-term outcomes.

Further, an assessment by the University of Calgary Health Technology Assessment Unit (Leggett et al., 2014) stated that, in adults with TRD, rTMS is more effective than no treatment but the optimal protocol remains unclear. The assessment found that few studies have reported on the effectiveness of rTMS
compared to ECT. The assessment stated that pooled estimates for response and remission provide conflicting results indicating rTMS may be more effective at achieving response but less effective at achieving remission. The assessment concluded that the effectiveness of rTMS compared to ECT remains unclear. The assessment also concluded that the effectiveness in youth and young adult populations is uncertain.

From the published literature a systematic review by Leggett et al. in 2015 was performed to evaluate rTMS for treatment-resistant depression in young people, ages 13–25 years. Three prospective cohort studies with small patient populations (n=7–9) met inclusion criteria. Follow-ups ranged from one month to three years. Anxiety levels based on the Screen for Child Anxiety-Related Disorders Questionnaire were significantly lower but no significant difference was reported in the Suicide Ideation Questionnaire. The three-year study was a follow-up of an earlier study and suggested that the subjects did not experience worsening or improvement in depression severity over time without repeat rTMS. The third study reported a decrease in the mean Children’s Depression Rating Scale. Meta-analysis was not possible due to the limited data. The limited number and the low quality of the studies restrict the ability to draw generalized conclusions about the use of rTMS in this age group. The rTMS protocols were heterogeneous. Currently, FDA approved TMS devices are only approved for use in adult patients, age 18 years and older.

Several variations of administering repetitive TMS to patients with major depression have been studied including: accelerated repetitive TMS, high-dose repetitive TMS, theta-burst repetitive TMS, deep-repetitive TMS, low frequency rTMS (LFrTMS) (1 Hz) and bilateral repetitive TMS (Holtzheimer, 2015). A recent review of the evidence for TMS treatment of depression states that studies are being conducted to test a weak oscillating TMS device that is proposed to not cause seizures and therefore might enable home delivery of TMS for the treatment of schizophrenia and depression (George, et al., 2013). Currently, TMS is not recommended for use in the home nor are the devices FDA approved for in-home use.

The long-term effectiveness of TMS in naturalistic clinical practice settings was also evaluated following acute treatment for patients not benefiting from antidepressants (Dunner, et al 2014). Adult patients with a primary diagnosis of unipolar, non-psychotic major depressive disorder (DSM-IV clinical criteria), who did not benefit from antidepressant medication, received TMS treatment in 42 clinical practices. A total of 257 patients completed a course of acute TMS treatment and consented to follow-up over 52 weeks. Assessments were obtained at 3, 6, 9, and 12 months. The study was conducted between March 2010 and August 2012. Compared with pre-TMS baseline, there was a statistically significant reduction in mean total scores on the Clinical Global Impressions-Severity of Illness scale (primary outcome), 9-Item Patient Health Questionnaire, and Inventory of Depressive Symptoms-Self Report (IDS-SR) at the end of acute treatment (all p < 0.0001), which was sustained throughout follow-up (all p < 0.0001). The proportion of patients who achieved remission at the conclusion of acute treatment remained similar at conclusion of the long-term follow-up. Among 120 patients who met IDS-SR response or remission criteria at the end of acute treatment, 75 (62.5 %) continued to meet response criteria throughout long-term follow-up. After the first month, when the majority of acute TMS tapering was completed, 93 patients (36.2 %) received re-introduction of TMS. In this group, the mean (SD) number of TMS treatment days was 16.2 (21.1). The authors concluded that TMS demonstrated a statistically and clinically meaningful durability of acute benefit over 12 months of follow-up. This was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS retreatment for symptom recurrence. The main drawbacks of this study were: (i) its observational, naturalistic design (no concurrent control group), (ii) conclusions regarding the influence of concomitant treatments,
including the role of TMS re-introduction, cannot be fully explored, and (iii) analysis using an LOCF (last-observation-carried-forward) analysis method may exaggerate the consistency of the scores.

A large multi-center cohort examined the safety and tolerability of navigated Transcranial Magnetic Stimulation (nTMS) in neurosurgical patients (Tarapore et. al., 2016). Functional mapping with monopulse and repetitive nTMS was performed in 733 patients. In this cohort, 57% of patients had left-sided tumors, 50% had frontal tumors, and 50% had seizures secondary to the lesion. Side effects and pain intensity related to the procedure were documented. Patients undergoing monopulse stimulation underwent an average of 490 pulses while those undergoing repetitive stimulation received an average of 2268 pulses. During monopulse stimulation, 5.1% reported discomfort, and 0.4% reported pain. During repetitive stimulation, 23.4% reported discomfort and 69.5% reported pain. No seizures or other adverse events were observed. The authors concluded that nTMS is safe and well-tolerated in neurosurgical patients. Clinicians should consider expanding nTMS to patients with frequent seizures, but more evaluation is necessary to evaluate this risk fully. Additional studies are needed to determine if nTMS improves patient outcomes.

### Applicable Coding

#### CPT Codes

**Covered codes if criteria are met**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90867</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management</td>
</tr>
<tr>
<td>90868</td>
<td>; subsequent delivery and management, per session</td>
</tr>
<tr>
<td>90869</td>
<td>; subsequent motor threshold re-determination with delivery and management</td>
</tr>
</tbody>
</table>

**Non-covered codes (Experimental/Investigational/Unproven)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
</tbody>
</table>

#### HCPCS Codes

No applicable codes

### References:

2. DSM-V Diagnostic Criteria for Major Depressive Disorder. [https://images.pearsonclinical.com/images/assets/basc-3/basc3resources/DSM5_DiagnosticCriteria_MajorDepressiveDisorder.pdf](https://images.pearsonclinical.com/images/assets/basc-3/basc3resources/DSM5_DiagnosticCriteria_MajorDepressiveDisorder.pdf)


Disclaimer:
This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to health care providers or U of U Health Plans members.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

“University of Utah Health Plans” and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association